AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

FDA Advisory Committee Recommends Approval for Avedro’s Riboflavin Ophthalmic Solutions with UVA Irradiation for Corneal Collagen Cross-Linking to Treat Progressive Keratoconus and Corneal Ectasia

FDA Advisory Committee Recommends Approval for Avedro’s Riboflavin Ophthalmic Solutions with UVA Irradiation for Corneal Collagen Cross-Linking to Treat Progressive Keratoconus and Corneal Ectasia

February 27, 2015

Avedro, Inc., a Boston-based ophthalmic pharmaceutical and medical device company, announced today that on February 24, 2015 the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel of the Medical Devices Advisory Committee voted in support of approval for Avedro’s new drug application (NDA) for riboflavin ophthalmic solutions with UVA irradiation for use in corneal collagen cross-linking for the treatment of the conditions underlying progressive keratoconus or corneal ectasia following refractive surgery.

Concert Pharmaceuticals Reports Year End 2014 Financial Results

Concert Pharmaceuticals Reports Year End 2014 Financial Results

February 27, 2015

Conference Call Scheduled Today at 8:30 a.m. ET

Joule Is Poised For Significant Progress in 2015

Joule Is Poised For Significant Progress in 2015

February 23, 2015

Reaches major milestones in 2014 to enable broad industrialization of its carbon-neutral transportation fuels

Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

February 17, 2015

Positive early clinical results in three distinct investigational medicines and a strong financial position support advancement of the Agios portfolio into late stage development

Avedro Announces Date for FDA Advisory Committee Meeting

Avedro Announces Date for FDA Advisory Committee Meeting

February 17, 2015

Committee to Review Avedro’s NDA for Riboflavin Ophthalmic Solutions with UVA Irradiation on February 24, 2015

Syros Pharmaceuticals Presents New Data on Use of its Gene Control Platform for Predicting Drug Response

Syros Pharmaceuticals Presents New Data on Use of its Gene Control Platform for Predicting Drug Response

February 10, 2015

- Abstract at AACR Translation of the Cancer Genome meeting describes novel approach to discovery of gene control biomarkers -

Concert Pharmaceuticals Announces Appointment of James V. Cassella as Chief Development Officer

Concert Pharmaceuticals Announces Appointment of James V. Cassella as Chief Development Officer

February 4, 2015

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has appointed James V. Cassella, Ph.D. as Chief Development Officer. In this newly created role, Dr. Cassella will lead Concert's product development strategy and operations and will have responsibility for all preclinical, clinical and manufacturing activities.

T2 Biosystems and Canon U.S. Life Sciences Announce Joint Collaboration to Develop Novel Test Panel to Rapidly Detect Lyme Disease

T2 Biosystems and Canon U.S. Life Sciences Announce Joint Collaboration to Develop Novel Test Panel to Rapidly Detect Lyme Disease

February 3, 2015

Collaboration Leverages T2 Biosystems' Proprietary T2MR(R) Technology and Canon's Collective Expertise to Enable Improved Diagnostics